Fig 1: BMF was the target of miR-34c-5p. (A) Schematic representation of the miR-34c-5p putative target sites in BMF 3’UTR and alignment of miR-34c-5p with WT and Mut BMF 3’UTR showing pairing. The mutated nucleotides were underlined. (B and C) HA-VSMCs were transfected with miRNA NC, miR-34c-5p mimics, and miR-34c-5p inhibitors, and harvested for the examination of BMF mRNA and protein. (D) The WT-BMF 3’UTR and Mut-BMF 3’UTR were co-transfected with miR-34c-5p mimics or control oligos into HA-VSMCs. Forty-eight hours after transfection, luciferase activities were measured. (E and F) qRT-PCR and Western blot analysis showed the expression level of BMF in HA-VSMCs cultured with NG, OC, and HG. (G) HA-VSMCs were transfected with shRNAs NC and shlncRNA-ES3-2, and the protein level of BMF was detected by Western blot. The data are expressed as mean ± SD, n=3, *p<0.05, **p<0.005, ***p<0.0005. NG: normal glucose; OC: osmolarity control; HG: high glucose; NC: negative control.
Fig 2: Effects of BMF on the apoptosis of CSE-treated A549 cells. (A) The relative expression level of BMF in lentiviral transfected A549 cells. (B) Proliferation of untransfected and transfected CSE-treated A549 cells. (C) Apoptosis in untransfected and transfected CSE-treated A549 cells. (D) Mitochondrial morphology in untransfected and transfected CSE-treated A549 cells (scar bar = 1 μm). (E) mRNA levels of apoptosis-related molecules in untransfected and transfected CSE-treated A549 cells. (F) Levels of apoptosis-related proteins in untransfected and transfected CSE-treated A549 cells. In (A), ##P < 0.01 vs LV-oe-NC, &&P < 0.01 vs LV-sh-NC. In (B), ##P < 0.01 vs 10% CSE, &&P < 0.01 vs 10% CSE. *P < 0.05, **P < 0.01 vs 10% CSE.
Fig 3: Expression of BMF and BMF-AS1 in high glucose-induced VSMC calcification and senescence. (A) Alizarin Red S staining (n = 5/group). Scale bar in blue represents 1500 μm. (B) SA-β-gal staining showed senescence in VSMCs treated with NG, HO, or HG for 72 h (n = 5/group). Scale bar in white represents 100 μm. (C and D) qRT-PCR showing the expression of BMF and BMF-AS1 as fold changes relative to NG group (n = 5/group). (E) Immunofluorescence microscopy of the intracellular location of BMF in VSMCs cultured with NG and HG, respectively (n = 3/group). Scale bar in white represents 100 μm. (F) FISH showed the presence of BMF-AS1 in both the cytoplasm and nucleus in VSMCs cultured with NG and HG (n = 3/group). Scale bar in white represents 100 μm. The data were expressed as mean ± SD, one-way ANOVA for Fig 1. A-D. ***p<0.0005, compared with NG group. NG: 5 mM β-GP + 5 mM glucose; HO: 5 mM β-GP + 30 mM mannitol; HG: 5 mM β-GP + 30 mM glucose.
Fig 4: RP11-521C20.3 regulates BMF expression in CSE-treated A549 cells. (A) The relative expression level of lncRNA RP11-521C20.3 in lentiviral transfected A549 cells. (B and C) Levels of BMF mRNA and protein, respectively. ##P < 0.01 vs LV-oe-NC. &&P < 0.01 vs LV-sh-NC. *P < 0.05, **P < 0.01 vs 10% CSE.
Fig 5: Bmf-/- inhibits artery calcification and aging in diabetic mice. (A and B) Alizarin Red S staining and Von Kossa staining showing calcified aorta from WT, WT diabetic mice, Bmf-/+ diabetic mice and Bmf-/- diabetic mice (n = 5/group). Black arrows indicate calcified vessels. Scale bar in black represents 200 μm. (C) SA-β-gal staining showing aged aortas from the four groups of mice (n = 5/group). Green staining indicates aged tissues and black arrows indicate aging vessels. Scale bar in red represents 50 μm. The data were expressed as mean ± SD, one-way ANOVA for Fig 4. A-C. Quantification of positively stained areas was measured by Image-Pro Plus software (version 6.0). ***p < 0.0005, *p < 0.05, compared with WT.##p < 0.001, #p < 0.05, compared with Bmf-/+ diabetic mice. ns: non-significant. WT: wild type; DM: diabetes mellitus.
Supplier Page from Abcam for Anti-Bmf antibody